Fiduciary Trust Co Decreases Stake in Pfizer Inc. (NYSE:PFE)

Fiduciary Trust Co lessened its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 9.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 277,985 shares of the biopharmaceutical company's stock after selling 28,265 shares during the quarter. Fiduciary Trust Co's holdings in Pfizer were worth $7,375,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in the business. Retirement Wealth Solutions LLC purchased a new stake in shares of Pfizer during the 4th quarter worth approximately $26,000. Rialto Wealth Management LLC purchased a new stake in shares of Pfizer during the 4th quarter worth approximately $26,000. Clarity Asset Management Inc. purchased a new stake in shares of Pfizer during the 4th quarter worth approximately $27,000. Kohmann Bosshard Financial Services LLC purchased a new stake in shares of Pfizer during the 4th quarter worth approximately $28,000. Finally, Noble Wealth Management PBC purchased a new stake in shares of Pfizer during the 4th quarter worth approximately $31,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Trading Down 1.0%

Shares of PFE stock traded down $0.23 on Tuesday, reaching $22.86. 39,200,976 shares of the stock were exchanged, compared to its average volume of 48,723,223. The stock has a market cap of $129.97 billion, a P/E ratio of 16.21, a price-to-earnings-growth ratio of 0.64 and a beta of 0.58. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The firm has a 50 day moving average of $23.96 and a two-hundred day moving average of $25.48. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. During the same period in the prior year, the firm posted $0.82 EPS. The business's revenue for the quarter was down 7.8% on a year-over-year basis. On average, research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 annualized dividend and a yield of 7.52%. Pfizer's dividend payout ratio is currently 124.64%.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on PFE. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. UBS Group upped their target price on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Finally, The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $25.00 target price (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, four have given a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $29.17.

Insider Activity at Pfizer

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the stock in a transaction that occurred on Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.06% of the stock is owned by insiders.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.